Expression of the components of the Cip/Kip family in malignant lymphoma of the thyroid

Pathobiology

Volumn 71, Issue 3, 2004, Pages 164-170

  Ito, Yasuhiro ^a   Yoshida, Hiroshi ^a   Matsuzuka, Fumio ^a   Matsuura, Nariaki ^b   Nakamura, Yasushi ^c   Nakamine, Hirokazu ^c   Kakudo, Kennichi ^c   Kuma, Kanji ^a   Miyauchi, Akira ^a  

^a KUMA HOSPITAL   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Immunohistochemistry; Malignant lymphoma; p21; p27; p57; Thyroid

Indexed keywords

KI 67 ANTIGEN; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN P57;

ARTICLE; CANCER CELL; CANCER GRADING; CANCER GROWTH; CELL CYCLE; CELL PROLIFERATION; CHRONIC DISEASE; CLINICAL CHEMISTRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LABELING INDEX; LYMPHOCYTIC INFILTRATION; LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CANCER; THYROIDITIS;

CELL DIVISION; CHRONIC DISEASE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DISEASE PROGRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LYMPHOMA; NUCLEAR PROTEINS; THYROID NEOPLASMS; THYROIDITIS; TUMOR MARKERS, BIOLOGICAL;

EID: 1842560550     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076472     Document Type: Article

References (35)

1. Matsuzuka F, Miyauchi A, Katayama S, Narabayashi I, Ikeda H, Kuma K, Sugawara M: Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. Thyroid 1993;3:93-99.
2. Matsuzuka F, Fukata S, Kuma K, Miyauchi A, Kakudo K, Sugawara M: Gene rearrangement of immunoglobulin as a marker of thyroid lymphoma. World J Surg 1998;22:558-561.
3. Schlumberger MJ, Caillou B: Miscellaneous tumors of the thyroid. Thyroid, ed 8. Philadelphia, Lippincott, Williams & Wilkins, 2001, pp 944-948.
4. Derringer GA, Thompson LDR, Frommelt A, Bijwaard KE, Heffess CS, Abbondanzo SL: Malignant lymphoma of the thyroid gland. A clinicopathologic study of 108 cases. Am J Surg Pathol 2000;24:623-639.
5. Sasaki K, Murakami T, Kawasaki M: The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J Cell Physiol 1987;133:579-584.
6. Xiong Y, Hannon GI, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-704.
7. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A: p27/Kip 1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994;8:9-22.
8. Lee MH, Reynisdottir I, Massague J: Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995;9:639-649.
9. Aoyagi K, Hohfuji K, Yano S, Murakami N, Miyagi M, Takeda J, Shirouzu K: The expression of proliferating cell nuclear antigen, p53, p21, and apoptosis in primary gastric lymphoma. Surgery 2002;132:20-26.
10. Korkolopoulou PA, Angelopoulou MK, Kontopidou FN, Patsouris EV, Christodoulou PN, Kittas CN, Davaris P, Pangalis GA: Retinoblastoma gene product and p21 (WAF1, CIP1) protein expression in non-Hodgkin's lymphomas: A multivariate survival analysis. Leukemia Lymph 2001;40:647-658.
11. Kanavarous P, Stefanaki K, Vlachonikolis J, Papalazarou D, Rontogianni D, Arvanitis D, Antonakopoulos G, Gorgoulis V, Bai M, Agnantis NJ: Immunohistohemical expression of the p53, p21/Waf-1, Rb, p16 and Ki67 proteins in multiple myeloma. Anticancer Res 2000;20:4619-4626.
12. Kanavaros P, Bai M, Stefanaki K, Poussias G, Rontogianni D, Zioga E, Gorgoulis V, Agnantis NJ: Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphoma. Histol Histopathol 2001;16:377-386.
13. Kiviniemi M, Sauroja I, Rajamaki A, Punnonen K, Soderstrom KO, Salminen E: Cell cycle regulators p27 and pRb in lymphomas-correlation with histology and proliferating activity. Br J Cancer 2000;83:1161-1167.
14. Bai M, Vlachonikolis J, Agnantis N, Tsanou E, Dimou S, Nicolaides C, Stefanaki S, Pavlidis N, Kanavarous P: Low expression of p27 protrein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A, cyclin B1 in diffuse large B-cell lymphomas. Mod Pathol 2001;14:1105-1113.
15. Izban KF, Alkan S, Singleton TP, His ED: Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21/WAF1, p27/Kip1, and p53 in mantle cell lymphoma. Arch Pathol Lab Med 2000;124:1457-1462.
16. Erickson LA, Jin L, Wollan PC, Thompson GB, van Heerden J, Lloyd RV: Expression of p27 Kip1 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol 1998;11:169-174.
17. Ito Y, Yoshida H, Nakano K, Kobayashi K, Yokozawa T, Hirai K, Matsuzuka F, Matsuura N, Kuma K, Miyauchi A: Expression of p57/Kip2 protein in normal and neoplastic thyroid tissue. Int J Mol Med 2002;9:373-376.
18. Ito Y, Kobayashi T, Takeda T, Komoike Y, Wakasugi E, Tamaki Y, Tsujimoto M, Matsuura N, Monden M: Expression of p21 (WAF1/CIP1) protein in clinical thyroid tissues. Br J Cancer 1996;74:1269-1274.
19. Ito Y, Takeda T, Wakasa K, Tsujimoto M, Matuura N: Expression of p57/ Kip2 protein in pancreatic adenocarcinoma. Pancreas 2001;23:246-250.
20. Ito Y, Takeda T, Sakon M, Tsujimoto M, Monden M, Matsuura N: Expression of p57/Kip2 protein in hepatocellular carcinoma. Oncology 2001;61:221-225.
21. Ito Y, Takeda T, Sasaki Y, Sakon M, Yamada T, Ishiguro S, Imaoka S, Tsujimoto M, Monden M, Matsuura N: Expression of p57/Kip2 protein in extrahepatic bile duct carcinoma and intrahepatic cholangiocellular carcinoma. Liver 2002;22:145-149.
22. Matsumoto M, Furihata M, Ohtsuki Y, Sasaguri S, Ogoshi S: Immunohistochemical characterization of p57KIP2 expression in human esophageal squamous cell carcinoma. Anticancer Res 2000;20:1947-1952.
23. Liu XP, Kawauchi S, Oga A, Suehiro Y, Tsushimi K, Tsushimi M, Sasaki K: Combined examination of p27 (Kip1), p21(Waf1/Cip1) and p53 expression allows precise estimation of prognosis in patients with gastric carcinoma. Histopathology 2001;39:603-610.
24. Zhang H, Sun XF: Loss of p27 expression predicts poor prognosis in patients with Dukes' B stage or proximal colorectal cancer. Int J Oncol 2001;19:49-52.
25. Tsukamoto S, Sugio K, Sakada T, Ushijima C, Yamazaki K, Sugimachi K: Reduced expression of cell-cycle regulator p27 (Kip1) correlates with a shortened survival in non-small cell lung cancer. Lung Cancer 2001;34:83-90.
26. Fiorentino M, Altimari A, D'Errico A, Gabusi E, Chieco P, Masetti M, Grigioni WF: Low p27 expression is an independent predictor of survival for patients with either hilar or peripheral intrahepatic cholangiocarcinoma. Clin Cancer Res 2001;7:3994-3999.
27. Migita T, Oda Y, Naito S, Tsuneyoshi M: Low expression of p27 (Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer 2002;94:973-979.
28. Lacoste-Collin L, Gomez-Brouchet A, Escourrou G, Delisle MB, Levade T, Uro-Coste E: Expression of p27 (kip1) in bladder cancers: Immunohistochemical study and prognostic value in a series of 95 patients. Cancer Lett 2002;186:115-120.
29. Nitti D, Belluco C, Mammano E, Marchet A, Ambrosi A, Mencarelli R, Segato P, Lise M: Low level of p27 (Kip1) protein expression in gastric adenocarcinoma is associated wit disease progression and poor outcome. J Surg Oncol 2002;81:167-175.
30. Kirla Rm, Haapasalo HK, Kalimo H, Salminen EK: Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas. Cancer 2003;197:644-648.
31. Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, Nakao K, Taniguchi N, Monden M: Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 1999;30:90-99
32. Wakasugi E, Kobayashi T, Tamaki Y, Ito Y, Miyashiro I, Komoike Y, Takeda T, Shin E, Takatsuka Y, Kikkawa N, Monden T, Monden M: p21(WAF1/CIP1) and p53 protein expression in breast cancer. Am J Clin Pathol 1997;107:684-691.
33. Shoji T, Tanaka F, Takata T, Yanagiihara K, Otake Y, Hanaoka N, Miyahara R, Nakagawa T, Kawano Y, Ishikawa S, Katakura H, Wada H: Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 2002;20:3865-3871.
34. Sogawa N, Takiguchi N, Koda K, Oda K, Satomi D, Kato K, Ishikura H, Miyazaki M: Value of expression of p21 WAF1/CIP1 as a prognostic factor in advanced middle and lower rectal cancer patients treated with preoperative radio-chemotherapy. Int J Oncol 2002;21:787-793.
35. Cheung TH, Lo KW, Yu MM, Yim SF, Poon CS, Chung TK, Wong YF: Aberrant expression of p21 (WAF1/CIP1) and p27 (KIP1) in cervical carcinoma. Cancer Lett 2001;172:93-98.